Next Investors logo grey

Creso Pharma updates market on Colombian medical cannabis acquisition


Published 09-APR-2018 09:33 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma (ASX:CPH) has informed the market that it has extended the heads of agreement for its proposed acquisition of Colombian medical cannabis group, Kunna S.A.S., and its parent company, Kunna Canada, from 30 April to 31 May.

The extension enables Creso to continue to make steady and satisfactory progress toward completing due diligence in the foreseeable future and satisfying the conditions precedent under the HOA with Kunna S.A.S.

This strategic acquisition will give CPH a considerable foothold in the salient Latin American market. Significantly, it will also make CPH the only ASX-listed medicinal cannabis company with direct exposure to the Colombian market, and with the capacity to commercially cultivate medicinal-grade cannabis in the country.

Colombia is one of Latin America’s rapid-growth marijuana markets. Colombians spent $US86.3 million on cannabis in 2008, and consumption has grown at 15 per cent per year.

It is projected that by 2019, Colombia will contribute over 40.5 tonnes of cannabis derived oil to the buzzing global medicinal cannabis market.

However, the size of the market share Creso can secure remains to be seen at this stage, so if considering this stock for your portfolio, do your own research and seek professional financial advice.

More on Kunna

Kunna plans to develop phytotherapeutic products with a view to treating seizures, chronic pain, cancer, epilepsy, multiple sclerosis and other medical conditions.

In March last year, Kunna was granted a licence to produce, manufacture, market and export cannabis derivatives and products using extracts in Colombia by the Ministry of Health — making it one of only a small number of companies to have clinched such a licence.

Following this, Kunna applied for a licence to cultivate medicinal cannabis in Colombia, which it expects to be granted this month. In preparation for this, Kunna has laid out a research project which investigates plant genetics, disease and optimising cultivation.

Kunna has also identified a parcel of land ideally suited to medicinal cannabis cultivation. Once it receives its cultivation licence, it will immediately kick off a fully-fledged genetic and fertilisation project to obtain the optimal scalable crop for the premise selected.

It will then also progress stage two of its project development, which will substantially expand its land package and production of medicinal cannabis. Stage three, meanwhile, has potential to bring the company up to 600 hectares of cultivation property, subject to Colombian ministry quota grants.

Kunna is leveraging local resources and research, combined with access to vast cultivation property, to emerge as one of the lowest cost producers in the industry.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.